CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...
Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, ...
FIRMAGON (degarelix injection) 80mg and 120mg vials of powder for reconstitution by Ferring Ferring Pharmaceuticals announced the FDA has approved the trade name Firmagon (degarelix injection) for its ...
Longer time to PSA failure is thought to be desirable as it may be indicative of time to castrationresistant prostate cancer (CRPC) and may delay initiation of second-line therapy, which includes ...
Please provide your email address to receive an email when new articles are posted on . Men with prostate cancer assigned to degarelix had similar incidence of arrhythmia and less incidence of ...
A phase II study of pomegranate extract for men with rising prostate-specific antigen following primary therapy. Background: Comparative effectiveness of the gonadotropin-releasing hormone (GnRH) ...
Relugolix and degarelix are both effective in achieving and maintaining sustained castration in advanced prostate cancer. Relugolix’s oral form provides convenience, eliminating the need for frequent ...
ORLANDO—Prostate cancer (PCa) patients treated with degarelix have a lower risk of PSA failure or death compared with those treated with leuprolide, according to the findings of a long-term study. The ...
The trial design and the patient population have been previously described in detail. 17 Patients were randomly allocated to receive treatment with either degarelix using a starting dose of 240 mg ...
Degarelix is a new hormonal therapy from the GnRH receptor blocker class of agents that immediately blocks the GnRH receptor and achieves fast testosterone suppression without an initial surge. In the ...
New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-term Suppression of Testosterone - a hormone that stimulates prostate cancer growth. PARSIPPANY, N.J., Dec. 24 ...
Please provide your email address to receive an email when new articles are posted on . Today the FDA announced the approval of the gonadotropin-releasing hormone receptor inhibitor degarelix for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results